From Medscape Oncology

Medscape Medical News from the:

European Society for Medical Oncology (ESMO) Congress 2014

September 26 - 30, 2014; Madrid, Spain

Meeting Highlights at a Glance

Top News From ESMO 2014: Slideshow Targeted agents for breast cancer, melanoma, and lung cancer, and the promise of immunotherapies, headlined this year's meeting.

Conference News

ESMO Injecting Oncolytic Viruses in Melanoma: Durable Responses
Medscape Medical News, October 10, 2014
ESMO Going Beyond KRAS in Metastatic Colorectal Cancer
Medscape Medical News, October 9, 2014
ESMO New Marker for Better Chemo Response in NSCLC?
Medscape Medical News, October 8, 2014
ESMO Failed Cancer Vaccines Might Live Again With New Immune Drugs
Reuters Health Information, October 1, 2014
ESMO New Standard in Melanoma: Combo of BRAF and MEK Inhibitors
Medscape Medical News, September 30, 2014
ESMO Radiation Therapy Adds No Survival Benefit in Mesothelioma
Medscape Medical News, September 30, 2014
ESMO Cediranib Shows Potential in Advanced Cervical Cancer
Medscape Medical News, September 29, 2014
ESMO 'Impressive' Duration of Response With Nivolumab in Melanoma
Medscape Medical News, September 29, 2014

ESMO In NSCLC After Progression on First-line TKI, What Next?
Medscape Medical News, September 29, 2014
ESMO 'Unprecedented' Survival in Metastatic Breast Cancer
Medscape Medical News, September 28, 2014
ESMO Anamorelin: First Ever Drug for Cancer Cachexia?
Medscape Medical News, September 28, 2014
ESMO Chemo and Radiotherapy Safe for Fetus During Later Pregnancy
Medscape Medical News, September 28, 2014
ESMO Rolapitant Reduces Chemo-Induced Nausea and Vomiting
Medscape Medical News, September 27, 2014
ESMO Afatinib Shows Modest Benefit in Head and Neck Cancer
Medscape Medical News, September 27, 2014
ESMO Young European Oncologists Report High Levels of Burnout
Medscape Medical News, September 26, 2014
ESMO What's Hot at ESMO 2014
Medscape Medical News, September 18, 2014

Medscape Oncology© WebMD, LLC

MEDSCAPE ONCOLOGY INSIGHTS

Oncology's Unrecognized Crisis
Lidia Schapira, MD; Susana Banerjee, MBBS, MRCP, PhD
Targeting an Unmet Need in Gastric Cancer
Florian Lordick, MD, PhD; Linda Brookes, MSc
Germline Genetics in Cancer: From Screening to Treatment
Linda Brookes, MSc
Confirmed: Abiraterone Ups Overall Survival in mCRPC
Stéphane Oudard, MD, PhD; Cora Sternberg, MD
Refining Sunitinib Use Extends Survival in RCC
Bernard Escudier, MD
The 'Fab Five' Rock Lymphoma
Martin Dreyling, MD, PhD
BRAF/MEK Increases Overall Survival in Melanoma
Antoni Ribas, MD, PhD
Positive Findings for HER2-Negative Breast Cancer
Fabrice André, MD, PhD; Gunter von Minckwitz, MD, PhD
Use 'TKI as Long as You Can' in NSCLC
Giorgio V. Scagliotti, MD, PhD; Tony Mok, MD
Can CRC Maintenance Therapy Extend Survival?
David J. Kerr, CBE, MD, DSc, FRCP, FMedSci; Dirk Arnold, MD
ESMO Guideline for Mantle Cell Lymphoma
Martin H. Dreyling, MD, PhD; Linda Brookes, MSc
ESMO Preview: Precision Medicine and Picasso
David J. Kerr, CBE, MD, DSc, FRCP, FMedSci

Previous Coverage